Discovery of novel indazole-linked triazoles as antifungal agents

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 12, 2007, Pages 3486-3490

  Park, Joon Seok ^a   Yu, Kyung A ^b   Kang, Tae Hee ^a   Kim, Sunghoon ^a   Suh, Young Ger ^a  

^a Seoul National University   (South Korea)

^b Daewoong Pharmaceutical Co Ltd   (South Korea)

Author keywords

Antifungal agents; Infection; Triazoles

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 3 (INDAZOL 1 YL) 1 (1,2,4 TRIAZOL 1 YL)BUTAN 2 OL DERIVATIVE; ALBACONAZOLE; AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; INDAZOLE DERIVATIVE; RAVUCONAZOLE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; IN VITRO STUDY; IN VIVO STUDY; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; SURVIVAL RATE;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS; CANDIDA; DISEASE MODELS, ANIMAL; INDAZOLES; MICE; MICROBIAL SENSITIVITY TESTS; RATS; STEREOISOMERISM; TRIAZOLES;

ASPERGILLUS; CANDIDA; CANDIDA ALBICANS; MURINAE; MUS;

EID: 34249330953     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.03.074     Document Type: Article

References (28)

1. Sheehan D.J., Hitchcock C.A., and Sibley C.M. Clin. Microbiol. Rev. 12 (1999) 40
2. Vanden Bossche H. In: McGuinnis M.R. (Ed). Curr. Top. Med. Mycol. Vol. 1 (1985), Springer, Berlin 313
3. Aoyama Y., Yoshida Y., and Sato R. J. Biol. Chem. 259 (1984) 1661
4. Trzaskos J.M., Bowen W.D., Shafiee A., Fischer R.T., and Gaylor J.L. J. Biol. Chem. 259 (1984) 13402
5. Karyotakis N.C., and Anaissie E.J. Curr. Opin. Inf. Dis. 7 (1994) 658
6. Zervos M., and Meunier F. Int. J. Antimicrob. Agents 3 (1993) 147
7. Como A.C., and Dismukes W.E. New Engl. J. Med. 330 (1994) 263
8. Dickinson R.P., Bell A.S., Hitchcock C.A., Nayayanaswami S., Ray S.J., Richardson K., and Troke P.F. Bioorg. Med. Chem. Lett. 6 (1996) 2031
9. Herbrecht R. Expert Rev. AntiInfect. Ther. 2 (2004) 485
10. Bartroli J., Turmo E., Alguero M., Boncompte E., Vericat M.L., Conte L., Ramis J., Merlos M., Garcia-Rafanell J., and Forn J. J. Med. Chem. 41 (1998) 1869
11. Ramos G., Cuenca-Estrella M., Monzon A., and Rodriguez-Tudela J.L. J. Antimicrob. Chemother. 44 (1999) 283
12. Sorbera L.A., Bartroli J., and Castañer J. Drugs Future 28 (2003) 529
13. Tsuruoka A., Kaku Y., Kakinuma H., Tsukada I., Yanagisawa M., Nara K., and Naito T. Chem. Pharm. Bull. 46 (1998) 623
14. Fung-Tomc J.C., Huczko E., Minassian B., and Bonner D.P. Antimicrob. Agents Chemother. 42 (1998) 313
15. Hata K., Kimura J., Miki H., Toyosawa T., Moriyama M., and Katsu K. Antimicrob. Agents Chemother. 40 (1996) 2243
16. Tasaka A., Tamura N., Matsushita Y., Teranishi K., Hayashi R., Okonogi K., and Itoh K. Chem. Pharm. Bull. 41 (1993) 1035
17. Konosu T., Tajima Y., Takeda N., Miyaoka T., Kasahara M., Yasuda H., and Oida S. Chem. Pharm. Bull. 38 (1990) 2476
18. Richardson K., Cooper K., Marriott M.S., Tarbit M.H., Troke P.F., and Whittle P.J. Ann. N.Y. Acad. Sci. 544 (1988) 6
19. Tasaka A., Tsuchimori N., Kitazaki T., Hiroe K., Hayashi R., Okonogi K., and Itoh K. Chem. Pharm. Bull. 43 (1995) 441
20. Singh, I. P.; Sidhu, I.; Palak, B. U.S. Patent 6,133,485, 2000.
21. Tasaka A., Tamura N., Matsushita Y., Kitazaki T., Hayashi R., Okonogi K., and Itoh K. Chem. Pharm. Bull. 43 (1995) 432
22. Kitazaki T., Ichikawa T., Tasaka A., Hosono H., Matsushita Y., Hayashi R., Okonogi K., and Itoh K. Chem. Pharm. Bull. 48 (2000) 1935
23. 3 only.
24. Isin E., de Jonge M., and Castagnoli Jr. N. J. Org. Chem. 66 (2001) 4220
25. Souers A., Gao J., Brune M., Bush E., Wodka D., Vasudevan A., Judd A., Mulhern M., Brodjian S., Dayton B., Shapiro R., Hernandez L., Marsh C., Sham H., Collins C., and Kym P. J. Med. Chem. 48 (2005) 1318
26. Ryu C.K., Kang H.Y., Yi Y.J., Shin K.H., and Lee B.H. Bioorg. Med. Chem. Lett. 10 (2000) 1589
27. Rodriguez R., and Acosta D. Toxicology 96 (1995) 83
28. 5 per animal). Treatment of the selected analogs, which were orally administered, was started after 2 h post-infection and the antifungal agents were given once a day for 7 consecutive days. All the analogs were administered with 20 mg/kg of once daily doses. Efficacy was determined by mean of survival days for 21 or 28 days after infections.